Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs

Dhakal, Santosh; Hiremath, Jagadish; Bondra, Kathryn; Lakshmanappa, Yashavanth Shaan; Shyu, Duan-Liang; Ouyang, Kang; Kang, KiRyong; Binjawadagi, Basavaraj; Goodman, Jonathan T.; Tabynov, Kairat; Krakowka, Steven; Narasimhan, Balaji; Lee, Chang Won; Renukaradhya, Gourapura J.

doi:10.1016/j.jconrel.2016.12.039

Cited by 99 publications

(131 citation statements)

References 75 publications

Supporting

Mentioning

131

Contrasting

Order By: Relevance

“…Moreover, PLGA-NPs promote antigen internalization by APCs and facilitate antigen processing and presentation to naïve lymphocytes (113,114). For instance, spherical PLGA-NPs (200-300 nm of diameter) were used to encapsulate an inactivated Swine influenza virus (SwIV) H1N2 antigens (KAg) via water/oil/water double emulsion solvent evaporation (83). It was observed that pigs vaccinated twice with this preparation and challenged with a virulent heterologous influenza virus strain, have a significantly milder disease in comparison to non-vaccinated animals.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Nanoparticle-Based Vaccines Against Respiratory Viruses

et al. 2019

View full text Add to dashboard Cite

The respiratory mucosa is the primary portal of entry for numerous viruses such as the respiratory syncytial virus, the influenza virus and the parainfluenza virus. These pathogens initially infect the upper respiratory tract and then reach the lower respiratory tract, leading to diseases. Vaccination is an affordable way to control the pathogenicity of viruses and constitutes the strategy of choice to fight against infections, including those leading to pulmonary diseases. Conventional vaccines based on live-attenuated pathogens present a risk of reversion to pathogenic virulence while inactivated pathogen vaccines often lead to a weak immune response. Subunit vaccines were developed to overcome these issues. However, these vaccines may suffer from a limited immunogenicity and, in most cases, the protection induced is only partial. A new generation of vaccines based on nanoparticles has shown great potential to address most of the limitations of conventional and subunit vaccines. This is due to recent advances in chemical and biological engineering, which allow the design of nanoparticles with a precise control over the size, shape, functionality and surface properties, leading to enhanced antigen presentation and strong immunogenicity. This short review provides an overview of the advantages associated with the use of nanoparticles as vaccine delivery platforms to immunize against respiratory viruses and highlights relevant examples demonstrating their potential as safe, effective and affordable vaccines.

show abstract

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Nanoparticle-Based Vaccines Against Respiratory Viruses

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Vaccine was delivered through the intranasal route as a mist using a multi-dose vaccine delivery device (Prima Tech USA, Kenansville, NC, USA) in the final volume of 2 mL in PBS per dose as described previously. 36 Each dose of vaccine had 500 µg of the total ten peptides (50 µg of each peptide) either in soluble form or encapsulated in liposomes. A group of pigs received MSU adjuvant (5 mg/dose) co-administered with the vaccine formulation.…”

Section: Experimental Designmentioning

confidence: 99%

Liposomal nanoparticle-based conserved peptide influenza vaccine and monosodium urate crystal adjuvant elicit protective immune response in pigs

Dhakal¹,

Cheng²,

Salcido³

et al. 2018

IJN

Self Cite

View full text Add to dashboard Cite

BackgroundInfluenza (flu) is a constant threat to humans and animals, and vaccination is one of the most effective ways to mitigate the disease. Due to incomplete protection induced by current flu vaccines, development of novel flu vaccine candidates is warranted to achieve greater efficacy against constantly evolving flu viruses.MethodsIn the present study, we used liposome nanoparticle (<200 nm diameter)-based subunit flu vaccine containing ten encapsulated highly conserved B and T cell epitope peptides to induce protective immune response against a zoonotic swine influenza A virus (SwIAV) H1N1 challenge infection in a pig model. Furthermore, we used monosodium urate (MSU) crystals as an adjuvant and co-administered the vaccine formulation as an intranasal mist to flu-free nursery pigs, twice at 3-week intervals.ResultsLiposome peptides flu vaccine delivered with MSU adjuvant improved the hemagglutination inhibition antibody titer and mucosal IgA response against the SwIAV challenge and also against two other highly genetically variant IAVs. Liposomal vaccines also enhanced the frequency of peptides and virus-specific T-helper/memory cells and IFN-γ response. The improved specific cellular and mucosal humoral immune responses in adjuvanted liposomal peptides flu vaccine partially protected pigs from flu-induced fever and pneumonic lesions, and reduced the nasal virus shedding and viral load in the lungs.ConclusionOverall, our study shows great promise for using liposome and MSU adjuvant- based subunit flu vaccine through the intranasal route, and provides scope for future, pre-clinical investigations in a pig model for developing potent human intranasal subunit flu vaccines.

show abstract

“…PLGA NPs, for example, are being tested in pigs to induce cross-protection against evolving swine flu virus because they can encapsulate and protect inactivated viral antigens and controllably release cargo [41]. Additionally, PLGA NPs co-delivering whole virus antigen and multiple TLRas (TLR4a and TLR7a) have been used to elicit robust immunity against H1N1 influenza in rhesus macaques [35].…”

Section: Biomaterials Can Improve Immunogenicity and Durability Of Vamentioning

confidence: 99%